Acetaminophen intoxication during treatment: What you don't know can hurt you

Clinical Pediatrics

Volumn 39, Issue 3, 2000, Pages 133-144

  Kearns, Gregory L ^a,b,c   Leeder, J Steven ^a,b,c   Wasserman, Gary S ^a,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; CARBAMAZEPINE; CIGARETTE SMOKE; DEXAMETHASONE; ISONIAZID; OMEPRAZOLE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; XENOBIOTIC AGENT;

ARTICLE; COMORBIDITY; DIAGNOSTIC TEST; DIET RESTRICTION; DRUG INTOXICATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; LIVER TOXICITY; RISK FACTOR; STOMACH LAVAGE; TOXICOKINETICS;

EID: 0034020475     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280003900301     Document Type: Article

References (75)

1. Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr. 1997;130:300-304.
2. Heubi JE, Bien JP. Acetaminophen use in children: more is not better. J Pediatr. 1997;103:175-177.
3. Heubi JE, Barbacci MB, Zimmerman HJ. Therapeutic misadventures with acetaminophen: hepatotoxicity after multiple doses in children. J Pediatr. 1998;132:22-27.
4. Perry HE, Shannon MW. Efficacy of oral versus intravenous N-acetylcysteine (NAC) in acetaminophen overdose: results of an open-label clinical trial. J Pediatr. 1998;132:149-152.
5. Rumack BH. Acetaminophen overdose in children and adolescents. Pediatr Clin North Am. 1986;33:691-701.
6. Nogen AG, Bremner JE. Fatal acetaminophen overdosage in a young child. J Pediatr. 1978;92:832-833.
7. Wilson JT, Rasantikul V, Harbison R, Martin D. Death in an adolescent following overdose of acetaminophen and phenobarbital. Am J Dis Child. 1978;132:466-473.
8. Blake KV, Bailey D, Zientek GM, Hendeles L. Death of a child associated with multiple overdoses of acetaminophen. Clin Pharmacol. 1988;105: 125-128.
9. Webster PA, Roberts DW, Benson RW, Kearns GL. Acetaminophen toxicity in children: diagnostic confirmation using a specific antigenic biomarker. J Clin Pharmacol. 1996;36:397-402.
10. Wilson JT, Brown RD, Bocchini JA Jr, Kearns GL. Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in young febrite children. Ther Drug Monitor. 1982;4:147-180.
11. 1997 Physician's Desk Reference for Nonprescription Drugs, 18th ed. Montvale, NJ: Medical Economics Co., Inc.; 1997.
12. Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973;187:185-194.
13. Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic nectosis. IV. Role of glutathione. J Pharmacol Exp Ther. 1973;187:214-217.
14. Farber JL, Leonard TB, Kyle ME, et al. Peroxidation-dependent and peroxidation-independent mechanisms by which acetaminophen kills cultured rat hepatocytes. Arch Biochem Biophys. 1988;267:640-650.
15. Gerson RJ, Casini A, Gilfor D, et al. Oxygen-mediated cell injury in the killing of cultured hepatocytes by acetaminophen. Biochem Biophys Res Commun. 1985;126:1129-1137.
16. Pumford NR, Halmes NC. Protein targets of reactive intermediates of xenobiotics. Ann Rev Pharmacol Toxicol. 1997;37:91-117.
17. Pessayre D, Dolder A, Artigon J-Y, et al. Effect of fasting on metabolite-mediated hepatotoxicity in the rat. Gastroenterology. 1979;77:264-271.
18. Price VF, Miller MG, Jollow DJ. Mechanisms of fasting-induced potentiation of acetaminophen hepatotoxicity in the rat. Biochem Pharmacol. 1987; 36:427-433.
19. Nahata MC, Powell DA, Durrell DF, Miller MA. Acetaminophen accumulation in pediatric patients arter repeated therapeutic doses. Eur J Clin Pharmacol. 1984:27:57-59.
20. Lomaestro BM, Malone M. Glutathione in health and disease: pharmacotherapeutic issues. Ann Pharmacother. 1995;29:1263-1273.
21. Roberts DW, Bucci TJ, Benson RW, et al. Immunohistochemical localization and quantification of the 3(Cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity. Am J Phatol. 1991;138:359-371.
22. Spieilberg SP. Acetaminophen toxicity in human lymphocytes in vitro. J Pharmacol Exp Ther. 1980;213:395-398.
23. Patten CJ, Thomas PE, Guy RL, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol. 1993;6:511-518.
24. Chen I., Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther. 1996;60:651-660.
25. Thummel KE, Lee CA, Kunze KL, et al. Oxidation of acetaminophen to N-actyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol. 1993;45:1563-1569.
26. Anundi I, Lahteenmaki T, Rundgren M, et al. Zonation of acetaminophen metabolism and cytochrome P450 2E1-mediated toxicity studied in isolated periportal and perivenous hepatocytes. Biochem Pharmacol . 1993;45:1251-1259.
27. Hart SG, Cartun RW, Wyand DS, et al. Immunohistochemical localization of acetaminophen in target tissues of the CD-1 mouse: correspondence of covalent binding with toxicity. Fundam Appl Toxicol. 1995;24:260-274.
28. Fritz P, Behrie K, Beaune P, et al. Differential expression of drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical charaterization of cytochrome P4503A and glutathione-S-transferase. Histochemistry. 1993;99:443-451.
29. Debri K, Boobis AR, Davies DS, Edwards RJ. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues, Biochem Pharmacol. 1995;50:2047-2056.
30. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr. 1995;7:220-233.
31. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin North Am. 1997;44:55-77.
32. Gonzales FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet. 1994;26:59-70.
33. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. . 1995;5:259-274.
34. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. CRC Crit Rev Toxicol. 1992;22:1-14.
35. Oinonen T. Lindros KO. Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver. Biochem J. 1995;309:55-61.
36. Murray GI, Foster CO, Barnes TS, et al. Cytochrome P4501A expression in adult and fetal human liver. Carcino-genesis. 1992;13:165-169.
37. Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children and adults. Clin Pharmacol Ther. 1976;19:284-294.
38. Lieb-Lai MW. Sarnaik AP, Newton JN, et al. Metabolism and pharmacokinetics of acetaminophen in a severely poisoned young child. J Pediatr. 1984;105: 125-128.
39. Tredger JM, Thuluvath P, Williams R, Murray-Lyon IM. Metabolic basis for high paracetamol dosage without hepatic injury: a case study. Human Exp Toxicol. 1995;14:8-12.
40. Weinshilboum R. Raftogianis R, Wood T, et al. Sulfotransferase molecular pharmacogenetics. Proceedings, 3rd International Sulfation Workshop, Dryden, Scotland, September 22-25, 1996, p. 32.
41. Warholm M, Rane A. Alexandrie A-K, et al. Genotypic and phenotypic determination of polymorphic glutathione transferase T1 in a Swedish population. Pharmacogenetics. 1995;5:252-254.
42. Burchell B, Nebert DW, Nelson DR, et al. The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biol. 1991;10:487-494.
43. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209-218.
44. Chang KC, Lauer BA, Bell TD, Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet. 1978;1:1132-1133.
45. Jonkman JHG, Nicholson KG, Farrow PR, et al. Effects of α-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol. 1989;27:795-802.
46. Echizen H, Ohta Y, Shirataki H, et al. Effects of a subchronic treatment with natural human interferons on antipyrine clearance and liver function in patients with chronic hepatitis, Clin Pharmacol Ther. 1990;30:562-567.
47. Moochala SM, Lee EJD. Effects of recombinant human interferon alpha on arylhydrocarbon hydroxylase activity in cultured human peripheral lymphocytes. Life Sci. 1991;39:365-367.
48. Renton KW, Armstrong SG. Immunemediated downregulation of cytochrome P450 and related drug biotransformation. In: Dean JH, Luster MI, Munson AE, Kimber I, eds. Immunotoxicology and Immunopharmacology, 2nd ed. New York: Raven Press, Ltd.; 1994;501-512.
49. Blazka ME, Elwell MR, Holladay SD, et al. Histopathology of acetaminophen-induced liver changes: Role of interleukin 1α and tumor necrosis factor α. Toxicol Pathol. 1996;24:181-189.
50. Barker CW, Fagan JB, Pasco DS, Down-regulation of P4501A1 and P4501A2 mRNA expression in isolated hepatocytes by oxidative stress. J Biol Chem. 1994;269:3985-3990.
51. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure, Hepatology. 1995;22: 767-773.
52. Kearns GL. CYP3A4 modulates acetaminophen toxicity in man. Pediatr Res. 1994;35:85A.
53. Jollow DJ, Mitchell JR, Potter WZ., et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther. 1973; 187:195-202.
54. Potter WZ, Davis DC, Mitchell JR, et al. Acetaminophen-induced hepatic necrosis. III. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther. 1973;187:203-210.
55. Dahlin DC, Miwa GT, Lu AYH, Nelson SD. N-Acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA. 1984;81:1327-1331.
56. Albano E, Rundgren M, Harvison PJ, et al. Mechanisms of N-acetyl-p-benzoquinine imine cytotoxicity. Mol Pharmacol. 1985;28:306-311.
57. Streeter AJ, Dahlin DC, Nelson SD. Baillie TA. The covalent binding of acetaminophen to protein. Evidence for cysteine residues us major sites arylation in vitro. Chem-Biol Interact. 1984;48:319-366.
58. 14C] acetaminophen to mouse hepatic microsomal proteins: the specific binding to calreticulin and the two forms of the thioh:protein disulfide oxidoreductases. Chem Res Toxicol. 1996;9:1176-1182.
59. 2+ ATPase by acetaminophen. Biochem Pharmacol. 1988;37:2125-2131.
60. 2+. J Biol Chem. 1985;260:13035-13040.
61. Birge RB, Bartolome JB, Nishanian F.V, et al. Dissociation of covalent binding from the oxidative effects of acetaminophen. Biochem Pharmacol. 1988; 37:3383-3393.
62. Gillette JR. A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. I. Correlation of changes in covalent binding of reactivity metabolites with changes in the incidence and severity of toxicity. Biochem Pharmacol. 1974; 23:2785-2794.
63. Pumford NR, Martin BM, Hinson JA. A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. Biochem Biophys Res Commun. 1992;182:1348-1355.
64. Cohen SD, Pumford NR, Khairallah EA, et al. Seletive protein covalent binding and target organ toxicity. Toxicol Appl Pharmacol. 1997;143:1-12.
65. Punmford NR, Hinson JA, Potter DW, et al. Immunochemical quantitation of 3-(cystein-S-yl)acetaminophen adducts in serum and liver proteins of acteaminophen-treated mice. J Pharmacol Exp Ther. 1989;248:190-196.
66. Hinson JA, Roberts DW, Benson RWD, et al. Mechanism ol paracetamol toxicity (letter). Lancet. 1990; 335:732.
67. Corcoran GB, Racz WJ, Smith CV, Mitchell JR. Effects of N-acetylcysteine on acetaminophen covalent binding and hepatic necrosis in mice. J Pharmacol Exp Ther. 1985;232:864-872.
68. Bruno MK, Cohen SD, Khairallah EA. Antidotal effectiveness of N-acetylcysteine in reversing at acetaminophen-in-duced hepatotoxicity. Enhancement of the proteolysis of arylated proteins. Biochem Pharmacol. 1988;37:4319-4325.
69. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetycysteine in paracetamol-induced fulminant hepatic failure: a prospective controlled trial. Br Med J. 1991;303:1026-1029.
70. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynainics and oxygen transport in fulminant liver failure. N Engl J Med. 1991;324:1852-1857.
71. Smilkstein MJ, Bronstein AC, Linden C, et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med. 1991;20:1058-1063.
72. Tobias JD, Gregory DF, Deshpande JK. Ondansetron to prevent emesis following N-acetylcysteine for acetaminophen intoxication. Pediatr Emerg Care. 1992;8:345-346.
73. Flanagan RJ, Meredith TJ. Use of N-acetylcysteine in clinical toxicology. Am J Med. 1991;91:131S-139S.
74. Prescott LF, Illingworth RN, Critchley JAJH, et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2:1097-1100.
75. Alonso EM, Sokol RJ, Hart J, et al. Fulminant hepatitis associated with centrilobular hepatic necrosis in young children. J Pediatr. 1995;127:888-891.